{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T07:01:19Z","timestamp":1788850879848,"version":"build-2803163510"},"reference-count":124,"publisher":"Bentham Science Publishers Ltd.","issue":"18","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CTMC"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract:<\/jats:title>\n                    <jats:p>Influenza viruses (INFV), the Orthomyxoviridae family, are mainly transmitted among\nhumans via aerosols or droplets from the respiratory secretions. However, fomites could be a potential\ntransmission pathway. Annually, seasonal INFV infections account for 290-650 thousand\ndeaths worldwide. Currently, there are two classes of approved drugs to treat INFV infections, being\nneuraminidase (NA) inhibitors and blockers of matrix-2 (M2) ion channel. However, cases of\nresistance have been observed for both chemical classes, reducing the efficacy of treatment. The\nemergence of influenza outbreaks and pandemics calls for new antiviral molecules that are more effective,\nand that could overcome the current resistance to anti-influenza drugs. In this context, polyphenolic\ncompounds are found in various plants, and these have displayed different multi-target\napproaches against diverse pathogens. Among these, green tea (Camellia sinensis) catechins, in special\nepigallocatechin-3-O-gallate (EGCG), have demonstrated significant activities against the two\nmost relevant human INFV, subtypes A and lineages B. In this sense, EGCG has been found to be\na promising multi-target agent against INFV since it can act inhibiting NA, hemagglutination\n(HA), RNA-dependent RNA polymerase (RdRp), and viral entry\/adsorption. In general, the lack of\nknowledge about potential multi-target natural products prevents an adequate exploration of them,\nincreasing the time for developing multi-target drugs. Then, this review aimed to compile most relevant\nstudies showing the anti-INFV effects of EGCG and its derivatives, which could become antiviral\ndrug prototypes in the future.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/1568026622666220127112056","type":"journal-article","created":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T03:10:06Z","timestamp":1643339406000},"page":"1485-1500","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Multi-target Approaches of Epigallocatechin-3-O-gallate (EGCG) and its\nDerivatives against Influenza Viruses"],"prefix":"10.2174","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1527-4501","authenticated-orcid":true,"given":"Edeildo Ferreira","family":"da Silva-J\u00fanior","sequence":"first","affiliation":[{"name":"Institute of Chemistry and Biotechnology, Federal University of Alagoas, Melo Mota Avenue, 57072-970, AC Sim\u00f5es campus, Macei\u00f3, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandro Rocha","family":"Silva","sequence":"additional","affiliation":[{"name":"Institute of Chemistry and Biotechnology, Federal University of Alagoas, Melo Mota Avenue, 57072-970, AC Sim\u00f5es campus, Macei\u00f3, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","first-page":"461","volume":"87","year":"2012","unstructured":"Vaccines against influenza WHO position paper \u2013 November 2012. Wkly Epidemiol Rec WHO2012,87(47),461-476","journal-title":"Wkly Epidemiol Rec"},{"key":"ref=2","year":"2018","unstructured":"WHO. Vaccine-Preventable Diseases: Surveillance Standards 2018","journal-title":"Vaccine-Preventable Diseases: Surveillance Standards"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1016\/S0140-6736(11)61051-9","volume":"378","author":"Nair H.","year":"2011","unstructured":"Nair H.; Brooks W.A.; Katz M.; Roca A.; Berkley J.A.; Madhi S.A.; Simmerman J.M.; Gordon A.; Sato M.; Howie S.; Krishnan A.; Ope M.; Lindblade K.A.; Carosone-Link P.; Lucero M.; Ochieng W.; Kamimoto L.; Dueger E.; Bhat N.; Vong S.; Theodoratou E.; Chittaganpitch M.; Chimah O.; Balmaseda A.; Buchy P.; Harris E.; Evans V.; Katayose M.; Gaur B.; O\u2019Callaghan-Gordo C.; Goswami D.; Arvelo W.; Venter M.; Briese T.; Tokarz R.; Widdowson M-A.; Mounts A.W.; Breiman R.F.; Feikin D.R.; Klugman K.P.; Olsen S.J.; Gessner B.D.; Wright P.F.; Rudan I.; Broor S.; Sim\u00f5es E.A.; Campbell H.; Global burden of respiratory infections due to seasonal influenza in young children: A systematic review and meta-analysis. Lancet 2011,378(9807),1917-1930","journal-title":"Lancet"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/S0140-6736(17)33293-2","volume":"391","author":"Iuliano A.D.","year":"2018","unstructured":"Iuliano A.D.; Roguski K.M.; Chang H.H.; Muscatello D.J.; Palekar R.; Tempia S.; Cohen C.; Gran J.M.; Schanzer D.; Cowling B.J.; Wu P.; Kyncl J.; Ang L.W.; Park M.; Redlberger-Fritz M.; Yu H.; Espenhain L.; Krishnan A.; Emukule G.; van Asten L.; Pereira da Silva S.; Aungkulanon S.; Buchholz U.; Widdowson M-A.; Bresee J.S.; Azziz-Baumgartner E.; Cheng P-Y.; Dawood F.; Foppa I.; Olsen S.; Haber M.; Jeffers C.; MacIntyre C.R.; Newall A.T.; Wood J.G.; Kundi M.; Popow-Kraupp T.; Ahmed M.; Rahman M.; Marinho F.; Sotomayor Proschle C.V.; Vergara Mallegas N.; Luzhao F.; Sa L.; Barbosa-Ram\u00edrez J.; Sanchez D.M.; Gomez L.A.; Vargas X.B.; Acosta Herrera A.; Llan\u00e9s M.J.; Fischer T.K.; Krause T.G.; M\u00f8lbak K.; Nielsen J.; Trebbien R.; Bruno A.; Ojeda J.; Ramos H.; an der Heiden M.; del Carmen Castillo Signor L.; Serrano C.E.; Bhardwaj R.; Chadha M.; Narayan V.; Kosen S.; Bromberg M.; Glatman-Freedman A.; Kaufman Z.; Arima Y.; Oishi K.; Chaves S.; Nyawanda B.; Al-Jarallah R.A.; Kuri-Morales P.A.; Matus C.R.; Corona M.E.J.; Burmaa A.; Darmaa O.; Obtel M.; Cherkaoui I.; van den Wijngaard C.C.; van der Hoek W.; Baker M.; Bandaranayake D.; Bissielo A.; Huang S.; Lopez L.; Newbern C.; Flem E.; Gr\u00f8neng G.M.; Hauge S.; de Cos\u00edo F.G.; de Molt\u00f3 Y.; Castillo L.M.; Cabello M.A.; von Horoch M.; Medina Osis J.; Machado A.; Nunes B.; Rodrigues A.P.; Rodrigues E.; Calomfirescu C.; Lupulescu E.; Popescu R.; Popovici O.; Bogdanovic D.; Kostic M.; Lazarevic K.; Milosevic Z.; Tiodorovic B.; Chen M.; Cutter J.; Lee V.; Lin R.; Ma S.; Cohen A.L.; Treurnicht F.; Kim W.J.; Delgado-Sanz C.; de mateo Onta\u00f1\u00f3n S.; Larrauri A.; Le\u00f3n I.L.; Vallejo F.; Born R.; Junker C.; Koch D.; Chuang J-H.; Huang W-T.; Kuo H-W.; Tsai Y-C.; Bundhamcharoen K.; Chittaganpitch M.; Green H.K.; Pebody R.; Go\u00f1i N.; Chiparelli H.; Brammer L.; Mustaquim D.; Estimates of global seasonal influenza-associated respiratory mortality: A modelling study. Lancet 2018,391(10127),1285-1300","journal-title":"Lancet"},{"key":"ref=5","unstructured":"WHO. Influenza (Seasonal)."},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12929-019-0567-0","volume":"26","author":"Shie J.J.","year":"2019","unstructured":"Shie J.J.; Fang J.M.; Development of effective anti-influenza drugs: Congeners and conjugates - a review. J Biomed Sci 2019,26(1),84","journal-title":"J Biomed Sci"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/j.drudis.2020.06.004","volume":"25","author":"Kumar S.","year":"2020","unstructured":"Kumar S.; Goicoechea S.; Kumar S.; Pearce C.M.; Durvasula R.; Kempaiah P.; Rathi B.; Poonam.; Oseltamivir analogs with potent anti-influenza virus activity. Drug Discov Today 2020,25,1389-1402","journal-title":"Drug Discov Today"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1128\/mr.56.1.152-179.1992","volume":"56","author":"Webster R.G.","year":"1992","unstructured":"Webster R.G.; Bean W.J.; Gorman O.T.; Chambers T.M.; Kawaoka Y.; Evolution and ecology of influenza A viruses. Microbiol Rev 1992,56(1),152-179","journal-title":"Microbiol Rev"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1126\/science.1122818","volume":"312","author":"Kuiken T.","year":"2006","unstructured":"Kuiken T.; Holmes E.C.; McCauley J.; Rimmelzwaan G.F.; Williams C.S.; Grenfell B.T.; Host species barriers to influenza virus infections. Science (80) 2006,312,394-397","journal-title":"Science (80)"},{"key":"ref=10","unstructured":"WHO. Influenza."},{"key":"ref=11","year":"2005","unstructured":"Annex 3 - Recommendations for the Production and Control of Influenza Vaccine WHO2005","journal-title":"Annex 3 - Recommendations for the Production and Control of Influenza Vaccine"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.coviro.2019.01.006","volume":"35","author":"O\u2019Hanlon R.","year":"2019","unstructured":"O\u2019Hanlon R.; Shaw M.L.; Baloxavir marboxil: The new influenza drug on the market. Curr Opin Virol 2019,35,14-18","journal-title":"Curr Opin Virol"},{"key":"ref=13","author":"Tejus A.","year":"2021","unstructured":"Tejus A.; Mathur A.G.; Pradhan S.; Malik S.; Drug update - Baloxavir marboxil: Latest entrant into the arena of pharmacotherapy of influenza. Med J Armed Forces India [In press].2021","journal-title":"Med J Armed Forces India"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.jmii.2021.04.002","volume":"54","author":"Kuo Y.C.","year":"2021","unstructured":"Kuo Y.C.; Lai C.C.; Wang Y.H.; Chen C.H.; Wang C.Y.; Clinical efficacy and safety of Baloxavir marboxil in the treatment of influenza: A systematic review and meta-analysis of randomized controlled trials. J Microbiol Immunol Infect 2021,54(5),865-875","journal-title":"J Microbiol Immunol Infect"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"100486","DOI":"10.1016\/j.jbc.2021.100486","volume":"296","author":"Todd B.","year":"2021","unstructured":"Todd B.; Tchesnokov E.P.; G\u00f6tte M.; The active form of the influenza cap-snatching endonuclease inhibitor Baloxavir marboxil is a tight binding inhibitor. J Biol Chem 2021,296,100486","journal-title":"J Biol Chem"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.jiac.2020.10.018","volume":"27","author":"Skrzeczek A.","year":"2021","unstructured":"Skrzeczek A.; Ikeoka H.; Hirotsu N.; Ansaripour A.; Aball\u00e9a S.; Onishi Y.; Hill M.; Igarashi A.; Cost-effectiveness of Baloxavir marboxil compared to laninamivir for the treatment of influenza in Japan. J Infect Chemother 2021,27(2),296-305","journal-title":"J Infect Chemother"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/S0140-6736(05)67338-2","volume":"366","author":"Bright R.A.","year":"2005","unstructured":"Bright R.A.; Medina M.J.; Xu X.; Perez-Oronoz G.; Wallis T.R.; Davis X.M.; Povinelli L.; Cox N.J.; Klimov A.I.; Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: A cause for concern. Lancet 2005,366(9492),1175-1181","journal-title":"Lancet"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.antiviral.2017.08.004","volume":"146","author":"Gubareva L.V.","year":"2017","unstructured":"Gubareva L.V.; Besselaar T.G.; Daniels R.S.; Fry A.; Gregory V.; Huang W.; Hurt A.C.; Jorquera P.A.; Lackenby A.; Leang S-K.; Lo J.; Pereyaslov D.; Rebelo-de-Andrade H.; Siqueira M.M.; Takashita E.; Odagiri T.; Wang D.; Zhang W.; Meijer A.; Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015-2016. Antiviral Res 2017,146,12-20","journal-title":"Antiviral Res"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.coph.2016.08.003","volume":"30","author":"Naesens L.","year":"2016","unstructured":"Naesens L.; Stevaert A.; Vanderlinden E.; Antiviral therapies on the horizon for influenza. Curr Opin Pharmacol 2016,30,106-115","journal-title":"Curr Opin Pharmacol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.jpba.2015.03.014","volume":"111","author":"M\u00fcller P.","year":"2015","unstructured":"M\u00fcller P.; Downard K.M.; Catechin inhibition of influenza neuraminidase and its molecular basis with mass spectrometry. J Pharm Biomed Anal 2015,111,222-230","journal-title":"J Pharm Biomed Anal"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/S1473-3099(11)70318-8","volume":"12","author":"Hurt A.C.","year":"2012","unstructured":"Hurt A.C.; Chotpitayasunondh T.; Cox N.J.; Daniels R.; Fry A.M.; Gubareva L.V.; Hayden F.G.; Hui D.S.; Hungnes O.; Lackenby A.; Lim W.; Meijer A.; Penn C.; Tashiro M.; Uyeki T.M.; Zambon M.; Antiviral resistance during the 2009 influenza A H1N1 pandemic: Public health, laboratory, and clinical perspectives. Lancet Infect Dis 2012,12(3),240-248","journal-title":"Lancet Infect Dis"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1056\/NEJMc1003749","volume":"363","author":"van der Vries E.","year":"2010","unstructured":"van der Vries E.; Stelma F.F.; Boucher C.A.B.; Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus. N Engl J Med 2010,363(14),1381-1382","journal-title":"N Engl J Med"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1517\/17460441.2.5.697","volume":"2","author":"Lahlou M.","year":"2007","unstructured":"Lahlou M.; Screening of natural products for drug discovery. Expert Opin Drug Discov 2007,2(5),697-705","journal-title":"Expert Opin Drug Discov"},{"key":"ref=24","first-page":"789","volume":"86","author":"Patwardhan B.","year":"2004","unstructured":"Patwardhan B.; Vaidy A.D.B.; Chorghade M.; Ayurveda and natural products drug discovery. Curr Sci 2004,86,789-799","journal-title":"Curr Sci"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.drudis.2008.07.004","volume":"13","author":"Harvey A.L.","year":"2008","unstructured":"Harvey A.L.; Natural products in drug discovery. Drug Discov Today 2008,13(19-20),894-901","journal-title":"Drug Discov Today"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1016\/j.drudis.2014.08.006","volume":"19","author":"Koeberle A.","year":"2014","unstructured":"Koeberle A.; Werz O.; Multi-target approach for natural products in inflammation. Drug Discov Today 2014,19(12),1871-1882","journal-title":"Drug Discov Today"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.tifs.2021.05.023","volume":"114","author":"Zhang Z.","year":"2021","unstructured":"Zhang Z.; Zhang X.; Bi K.; He Y.; Yan W.; Yang C.S.; Zhang J.; Potential protective mechanisms of green tea polyphenol EGCG against COVID-19. Trends Food Sci Technol 2021,114,11-24","journal-title":"Trends Food Sci Technol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"110186","DOI":"10.1016\/j.biopha.2020.110186","volume":"127","author":"Zhang Y.","year":"2020","unstructured":"Zhang Y.; Lin H.; Liu C.; Huang J.; Liu Z.; A review for physiological activities of EGCG and the role in improving fertility in humans\/mammals. Biomed Pharmacother 2020,127,110186","journal-title":"Biomed Pharmacother"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1016\/j.bcp.2011.07.093","volume":"82","author":"Singh B.N.","year":"2011","unstructured":"Singh B.N.; Shankar S.; Srivastava R.K.; Green tea catechin, epigallocatechin-3-gallate (EGCG): Mechanisms, perspectives and clinical applications. Biochem Pharmacol 2011,82(12),1807-1821","journal-title":"Biochem Pharmacol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"S91","DOI":"10.1016\/j.freeradbiomed.2010.10.231","volume":"49","author":"Inacio J.D.","year":"2010","unstructured":"Inacio J.D.; Canto-Cavalheiro M.M.; Almeida-Amaral E.E.; The antileishmanial activity of epigallocatechin gallate on Leishmania braziliensis occur through reactive oxygen species production and mitochondrial disruption. Free Radic Biol Med 2010,49,S91","journal-title":"Free Radic Biol Med"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.exppara.2012.06.008","volume":"132","author":"Inacio J.D.F.","year":"2012","unstructured":"Inacio J.D.F.; Canto-Cavalheiro M.M.; Menna-Barreto R.F.; Almeida-Amaral E.E.; Mitochondrial damage contribute to epigallocatechin-3-gallate induced death in Leishmania amazonensis. Exp Parasitol 2012,132(2),151-155","journal-title":"Exp Parasitol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.exppara.2007.04.015","volume":"117","author":"G\u00fcida M.C.","year":"2007","unstructured":"G\u00fcida M.C.; Esteva M.I.; Camino A.; Flawi\u00e1 M.M.; Torres H.N.; Paveto C.; Trypanosoma cruzi: In vitro and in vivo antiproliferative effects of epigallocatechin gallate (EGCg). Exp Parasitol 2007,117(2),188-194","journal-title":"Exp Parasitol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ijpddr.2012.09.001","volume":"2","author":"Vigueira P.A.","year":"2012","unstructured":"Vigueira P.A.; Ray S.S.; Martin B.A.; Ligon M.M.; Paul K.S.; Effects of the green tea catechin (-)-epigallocatechin gallate on Trypanosoma brucei. Int J Parasitol Drugs Drug Res 2012,2,225-229","journal-title":"Int J Parasitol Drugs Drug Res"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.3390\/molecules23102475","volume":"23","author":"Kaihatsu K.","year":"2018","unstructured":"Kaihatsu K.; Yamabe M.; Ebara Y.; Antiviral mechanism of action of epigallocatechin-3-O-gallate and its fatty acid esters. Molecules 2018,23(10),2475","journal-title":"Molecules"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.3748\/wjg.v17.i11.1507","volume":"17","author":"He W.","year":"2011","unstructured":"He W.; Li L.X.; Liao Q.J.; Liu C.L.; Chen X.L.; Epigallocatechin gallate inhibits HBV DNA synthesis in a viral replication - inducible cell line. World J Gastroenterol 2011,17(11),1507-1514","journal-title":"World J Gastroenterol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1007\/BF02978215","volume":"28","author":"Lyu S-Y.","year":"2005","unstructured":"Lyu S-Y.; Rhim J-Y.; Park W-B.; Antiherpetic activities of flavonoids against herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) in vitro. Arch Pharm Res 2005,28(11),1293-1301","journal-title":"Arch Pharm Res"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1021\/jf052940e","volume":"54","author":"Savi L.A.","year":"2006","unstructured":"Savi L.A.; Barardi C.R.M.; Sim\u00f5es C.M.O.; Evaluation of antiherpetic activity and genotoxic effects of tea catechin derivatives. J Agric Food Chem 2006,54(7),2552-2557","journal-title":"J Agric Food Chem"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1128\/AAC.00825-07","volume":"52","author":"Isaacs C.E.","year":"2008","unstructured":"Isaacs C.E.; Wen G.Y.; Xu W.; Jia J.H.; Rohan L.; Corbo C.; Di Maggio V.; Jenkins E.C.; Hillier S.; Epigallocatechin gallate inactivates clinical isolates of herpes simplex virus. Antimicrob Agents Chemother 2008,52(3),962-970","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.antiviral.2010.10.007","volume":"89","author":"Gescher K.","year":"2011","unstructured":"Gescher K.; Hensel A.; Hafezi W.; Derksen A.; K\u00fchn J.; Oligomeric proanthocyanidins from Rumex acetosa L. inhibit the attachment of herpes simplex virus type-1. Antiviral Res 2011,89(1),9-18","journal-title":"Antiviral Res"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"5646","DOI":"10.1128\/AAC.05531-11","volume":"55","author":"Isaacs C.E.","year":"2011","unstructured":"Isaacs C.E.; Xu W.; Merz G.; Hillier S.; Rohan L.; Wen G.Y.; Digallate dimers of (-)-epigallocatechin gallate inactivate herpes simplex virus. Antimicrob Agents Chemother 2011,55(12),5646-5653","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"7806","DOI":"10.1128\/JVI.00896-14","volume":"88","author":"Colpitts C.C.","year":"2014","unstructured":"Colpitts C.C.; Schang L.M.; A small molecule inhibits virion attachment to heparan sulfate- or sialic acid-containing glycans. J Virol 2014,88(14),7806-7817","journal-title":"J Virol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.virusres.2018.03.015","volume":"249","author":"Pradhan P.","year":"2018","unstructured":"Pradhan P.; Nguyen M.L.; Herpes simplex virus virucidal activity of MST-312 and epigallocatechin gallate. Virus Res 2018,249,93-98","journal-title":"Virus Res"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s00280-012-2063-z","volume":"71","author":"He L.","year":"2013","unstructured":"He L.; Zhang E.; Shi J.; Li X.; Zhou K.; Zhang Q.; Le A.D.; Tang X.; (-)-Epigallocatechin-3-gallate inhibits human papillomavirus (HPV)-16 oncoprotein-induced angiogenesis in non-small cell lung cancer cells by targeting HIF-1\u03b1. Cancer Chemother Pharmacol 2013,71(3),713-725","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S0166-3542(02)00212-7","volume":"58","author":"Weber J.M.","year":"2003","unstructured":"Weber J.M.; Ruzindana-Umunyana A.; Imbeault L.; Sircar S.; Inhibition of adenovirus infection and adenain by green tea catechins. Antiviral Res 2003,58(2),167-173","journal-title":"Antiviral Res"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.virol.2016.06.012","volume":"496","author":"Carneiro B.M.","year":"2016","unstructured":"Carneiro B.M.; Batista M.N.; Braga A.C.S.; Nogueira M.L.; Rahal P.; The green tea molecule EGCG inhibits Zika virus entry. Virology 2016,496,215-218","journal-title":"Virology"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.ijbiomac.2017.06.105","volume":"104","author":"Sharma N.","year":"2017","unstructured":"Sharma N.; Murali A.; Singh S.K.; Giri R.; Epigallocatechin gallate, an active green tea compound inhibits the Zika virus entry into host cells via binding the envelope protein. Int J Biol Macromol 2017,104(Pt A),1046-1054","journal-title":"Int J Biol Macromol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.3389\/fmicb.2017.01314","volume":"8","author":"V\u00e1zquez-Calvo \u00c1.","year":"2017","unstructured":"V\u00e1zquez-Calvo \u00c1.; Jim\u00e9nez de Oya N.; Mart\u00edn-Acebes M.A.; Garcia-Moruno E.; Saiz J-C.; Antiviral properties of the natural polyphenols delphinidin and epigallocatechin gallate against the Flaviviruses West Nile Virus, Zika Virus, and Dengue Virus. Front Microbiol 2017,8,1314","journal-title":"Front Microbiol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1007\/s00705-018-3769-y","volume":"163","author":"Raekiansyah M.","year":"2018","unstructured":"Raekiansyah M.; Buerano C.C.; Luz M.A.D.; Morita K.; Inhibitory effect of the green tea molecule EGCG against dengue virus infection. Arch Virol 2018,163(6),1649-1655","journal-title":"Arch Virol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.antiviral.2007.06.001","volume":"76","author":"Zuo G.","year":"2007","unstructured":"Zuo G.; Li Z.; Chen L.; Xu X.; Activity of compounds from Chinese herbal medicine Rhodiola kirilowii (Regel) Maxim against HCV NS3 serine protease. Antiviral Res 2007,76(1),86-92","journal-title":"Antiviral Res"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1002\/hep.24610","volume":"54","author":"Ciesek S.","year":"2011","unstructured":"Ciesek S.; von Hahn T.; Colpitts C.C.; Schang L.M.; Friesland M.; Steinmann J.; Manns M.P.; Ott M.; Wedemeyer H.; Meuleman P.; Pietschmann T.; Steinmann E.; The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry. Hepatology 2011,54(6),1947-1955","journal-title":"Hepatology"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1002\/hep.24803","volume":"55","author":"Calland N.","year":"2012","unstructured":"Calland N.; Albecka A.; Belouzard S.; Wychowski C.; Duverlie G.; Descamps V.; Hober D.; Dubuisson J.; Rouill\u00e9 Y.; S\u00e9ron K.; (-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry. Hepatology 2012,55(3),720-729","journal-title":"Hepatology"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"4162","DOI":"10.1016\/j.bmcl.2014.07.051","volume":"24","author":"Bhat R.","year":"2014","unstructured":"Bhat R.; Adam A.T.; Lee J.J.; Deloison G.; Rouill\u00e9 Y.; S\u00e9ron K.; Rotella D.P.; Structure-activity studies of (-)-epigallocatechin gallate derivatives as HCV entry inhibitors. Bioorg Med Chem Lett 2014,24(17),4162-4165","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"10053","DOI":"10.1128\/JVI.01473-15","volume":"89","author":"Calland N.","year":"2015","unstructured":"Calland N.; Sahuc M-E.; Belouzard S.; P\u00e8ne V.; Bonnafous P.; Mesalam A.A.; Deloison G.; Descamps V.; Sahpaz S.; Wychowski C.; Lambert O.; Brodin P.; Duverlie G.; Meuleman P.; Rosenberg A.R.; Dubuisson J.; Rouill\u00e9 Y.; S\u00e9ron K.; Polyphenols inhibit hepatitis C virus entry by a new mechanism of action. J Virol 2015,89(19),10053-10063","journal-title":"J Virol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"938","DOI":"10.3390\/v6020938","volume":"6","author":"Zhao C.","year":"2014","unstructured":"Zhao C.; Liu S.; Li C.; Yang L.; Zu Y.; In vitro evaluation of the antiviral activity of the synthetic epigallocatechin gallate analog-epigallocatechin gallate (EGCG) palmitate against porcine reproductive and respiratory syndrome virus. Viruses 2014,6(2),938-950","journal-title":"Viruses"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.bbrc.2017.07.157","volume":"491","author":"Lu J.W.","year":"2017","unstructured":"Lu J.W.; Hsieh P.S.; Lin C.C.; Hu M.K.; Huang S.M.; Wang Y.M.; Liang C.Y.; Gong Z.; Ho Y.J.; Synergistic effects of combination treatment using EGCG and suramin against the chikungunya virus. Biochem Biophys Res Commun 2017,491(3),595-602","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.antiviral.2014.07.004","volume":"109","author":"Reid S.P.","year":"2014","unstructured":"Reid S.P.; Shurtleff A.C.; Costantino J.A.; Tritsch S.R.; Retterer C.; Spurgers K.B.; Bavari S.; HSPA5 is an essential host factor for Ebola virus infection. Antiviral Res 2014,109,171-174","journal-title":"Antiviral Res"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/BF02253344","volume":"1","author":"Chang C.W.","year":"1994","unstructured":"Chang C.W.; Hsu F.L.; Lin J.Y.; Inhibitory effects of polyphenolic catechins from chinese green tea on HIV reverse transcriptase activity. J Biomed Sci 1994,1(3),163-166","journal-title":"J Biomed Sci"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1016\/S0960-894X(01)00577-7","volume":"11","author":"Tillekeratne L.M.","year":"2001","unstructured":"Tillekeratne L.M.; Sherette A.; Grossman P.; Hupe L.; Hupe D.; Hudson R.A.; Simplified catechin-gallate inhibitors of HIV-1 reverse transcriptase. Bioorg Med Chem Lett 2001,11(20),2763-2767","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0091-6749(03)02007-4","volume":"112","author":"Kawai K.","year":"2003","unstructured":"Kawai K.; Tsuno N.H.; Kitayama J.; Okaji Y.; Yazawa K.; Asakage M.; Hori N.; Watanabe T.; Takahashi K.; Nagawa H.; Epigallocatechin gallate, the main component of tea polyphenol, binds to CD4 and interferes with gp120 binding. J Allergy Clin Immunol 2003,112(5),951-957","journal-title":"J Allergy Clin Immunol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.bbagen.2005.02.012","volume":"1723","author":"Liu S.","year":"2005","unstructured":"Liu S.; Lu H.; Zhao Q.; He Y.; Niu J.; Debnath A.K.; Wu S.; Jiang S.; Theaflavin derivatives in black tea and catechin derivatives in green tea inhibit HIV-1 entry by targeting gp41. Biochim Biophys Acta 2005,1723(1-3),270-281","journal-title":"Biochim Biophys Acta"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1016\/j.jaci.2006.08.016","volume":"118","author":"Williamson M.P.","year":"2006","unstructured":"Williamson M.P.; McCormick T.G.; Nance C.L.; Shearer W.T.; Epigallocatechin gallate, the main polyphenol in green tea, binds to the T-cell receptor, CD4: Potential for HIV-1 therapy. J Allergy Clin Immunol 2006,118(6),1369-1374","journal-title":"J Allergy Clin Immunol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.jaci.2008.12.024","volume":"123","author":"Nance C.L.","year":"2009","unstructured":"Nance C.L.; Siwak E.B.; Shearer W.T.; Preclinical development of the green tea catechin, epigallocatechin gallate, as an HIV-1 therapy. J Allergy Clin Immunol 2009,123(2),459-465","journal-title":"J Allergy Clin Immunol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.clim.2010.08.007","volume":"137","author":"Jiang F.","year":"2010","unstructured":"Jiang F.; Chen W.; Yi K.; Wu Z.; Si Y.; Han W.; Zhao Y.; The evaluation of catechins that contain a galloyl moiety as potential HIV-1 integrase inhibitors. Clin Immunol 2010,137(3),347-356","journal-title":"Clin Immunol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3851\/IMP1774","volume":"21","author":"Li S.","year":"2011","unstructured":"Li S.; Hattori T.; Kodama E.N.; Epigallocatechin gallate inhibits the HIV reverse transcription step. Antivir Chem Chemother 2011,21(6),239-243","journal-title":"Antivir Chem Chemother"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1742-6405-9-2","volume":"9","author":"Hartjen P.","year":"2012","unstructured":"Hartjen P.; Frerk S.; Hauber I.; Matzat V.; Thomssen A.; Holstermann B.; Hohenberg H.; Schulze W.; Schulze Zur Wiesch J.; van Lunzen J.; Assessment of the range of the HIV-1 infectivity enhancing effect of individual human semen specimen and the range of inhibition by EGCG. AIDS Res Ther 2012,9(1),2","journal-title":"AIDS Res Ther"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1242\/bio.010215","volume":"4","author":"Castellano L.M.","year":"2015","unstructured":"Castellano L.M.; Hammond R.M.; Holmes V.M.; Weissman D.; Shorter J.; Epigallocatechin-3-gallate rapidly remodels PAP85-120, SEM1(45-107), and SEM2(49-107) seminal amyloid fibrils. Biol Open 2015,4(9),1206-1212","journal-title":"Biol Open"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.intimp.2017.08.023","volume":"52","author":"Xu M.J.","year":"2017","unstructured":"Xu M.J.; Liu B.J.; Wang C.L.; Wang G.H.; Tian Y.; Wang S.H.; Li J.; Li P.Y.; Zhang R.H.; Wei D.; Tian S.F.; Xu T.; Epigallocatechin-3-gallate inhibits TLR4 signaling through the 67-kDa laminin receptor and effectively alleviates acute lung injury induced by H9N2 swine influenza virus. Int Immunopharmacol 2017,52,24-33","journal-title":"Int Immunopharmacol"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"112671","DOI":"10.1016\/j.jep.2020.112671","volume":"253","author":"Zhang T.","year":"2020","unstructured":"Zhang T.; Lo C.Y.; Xiao M.; Cheng L.; Pun Mok C.K.; Shaw P.C.; Anti-influenza virus phytochemicals from Radix Paeoniae Alba and characterization of their neuraminidase inhibitory activities. J Ethnopharmacol 2020,253,112671","journal-title":"J Ethnopharmacol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3201\/eid1209.05-0979","volume":"12","author":"Taubenberger J.K.","year":"2006","unstructured":"Taubenberger J.K.; Morens D.M.; 1918 Influenza: The mother of all pandemics. Emerg Infect Dis 2006,12(1),15-22","journal-title":"Emerg Infect Dis"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"e21828","DOI":"10.1371\/journal.pone.0021828","volume":"6","author":"Kelly H.","year":"2011","unstructured":"Kelly H.; Peck H.A.; Laurie K.L.; Wu P.; Nishiura H.; Cowling B.J.; The age-specific cumulative incidence of infection with pandemic influenza H1N1 2009 was similar in various countries prior to vaccination. PLoS One 2011,6(8),e21828","journal-title":"PLoS One"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S1473-3099(12)70121-4","volume":"12","author":"Dawood F.S.","year":"2012","unstructured":"Dawood F.S.; Iuliano A.D.; Reed C.; Meltzer M.I.; Shay D.K.; Cheng P-Y.; Bandaranayake D.; Breiman R.F.; Brooks W.A.; Buchy P.; Feikin D.R.; Fowler K.B.; Gordon A.; Hien N.T.; Horby P.; Huang Q.S.; Katz M.A.; Krishnan A.; Lal R.; Montgomery J.M.; M\u00f8lbak K.; Pebody R.; Presanis A.M.; Razuri H.; Steens A.; Tinoco Y.O.; Wallinga J.; Yu H.; Vong S.; Bresee J.; Widdowson M-A.; Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: A modelling study. Lancet Infect Dis 2012,12(9),687-695","journal-title":"Lancet Infect Dis"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.compbiolchem.2017.11.001","volume":"71","author":"Kannan S.","year":"2017","unstructured":"Kannan S.; Kolandaivel P.; Antiviral potential of natural compounds against influenza virus hemagglutinin. Comput Biol Chem 2017,71,207-218","journal-title":"Comput Biol Chem"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/B978-0-12-384937-3.00099-9","volume":"1918","author":"Song J.M.","year":"2013","unstructured":"Song J.M.; Seong B.L.; Anti-influenza viral activity of catechins and derivatives. Tea Heal Dis Prev 2013,1918,1185-1193","journal-title":"Tea Heal Dis Prev"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"e00070","DOI":"10.1128\/mBio.00070-14","volume":"5","author":"Dubois J.","year":"2014","unstructured":"Dubois J.; Terrier O.; Rosa-Calatrava M.; Influenza viruses and mRNA splicing: Doing more with less. MBio 2014,5(3),e00070-e14","journal-title":"MBio"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14218\/ERHM.2016.00013","volume":"2","author":"Adeola O.A.","year":"2017","unstructured":"Adeola O.A.; Treatment of influenza: Prospects of post-transcriptional gene silencing through synthetic SiRNAs. Explor Res Hypothesis Med 2017,2(1),1-2","journal-title":"Explor Res Hypothesis Med"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s13104-016-2083-6","volume":"9","author":"Vasin A.V.","year":"2016","unstructured":"Vasin A.V.; Petrova A.V.; Egorov V.V.; Plotnikova M.A.; Klotchenko S.A.; Karpenko M.N.; Kiselev O.I.; The influenza A virus NS genome segment displays lineage-specific patterns in predicted RNA secondary structure. BMC Res Notes 2016,9(1),279","journal-title":"BMC Res Notes"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1099\/vir.0.026187-0","volume":"92","author":"Jackson D.","year":"2011","unstructured":"Jackson D.; Elderfield R.A.; Barclay W.S.; Molecular studies of influenza B virus in the reverse genetics era. J Gen Virol 2011,92(Pt 1),1-17","journal-title":"J Gen Virol"},{"key":"ref=78","first-page":"153","volume":"82","author":"Samji T.","year":"2009","unstructured":"Samji T.; Influenza A.; Influenza A: Understanding the viral life cycle. Yale J Biol Med 2009,82(4),153-159","journal-title":"Yale J Biol Med"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"13166","DOI":"10.1073\/pnas.152456799","volume":"99","author":"Honda A.","year":"2002","unstructured":"Honda A.; Mizumoto K.; Ishihama A.; Minimum molecular architectures for transcription and replication of the influenza virus. Proc Natl Acad Sci USA 2002,99(20),13166-13171","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/nature07720","volume":"458","author":"Yuan P.","year":"2009","unstructured":"Yuan P.; Bartlam M.; Lou Z.; Chen S.; Zhou J.; He X.; Lv Z.; Ge R.; Li X.; Deng T.; Fodor E.; Rao Z.; Liu Y.; Crystal structure of an avian influenza polymerase PA(N) reveals an endonuclease active site. Nature 2009,458(7240),909-913","journal-title":"Nature"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"6855","DOI":"10.1074\/jbc.C800224200","volume":"284","author":"Kuzuhara T.","year":"2009","unstructured":"Kuzuhara T.; Kise D.; Yoshida H.; Horita T.; Murazaki Y.; Nishimura A.; Echigo N.; Utsunomiya H.; Tsuge H.; Structural basis of the influenza A virus RNA polymerase PB2 RNA-binding domain containing the pathogenicity-determinant lysine 627 residue. J Biol Chem 2009,284(11),6855-6860","journal-title":"J Biol Chem"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/nature07745","volume":"458","author":"Dias A.","year":"2009","unstructured":"Dias A.; Bouvier D.; Cr\u00e9pin T.; McCarthy A.A.; Hart D.J.; Baudin F.; Cusack S.; Ruigrok R.W.H.; The cap-snatching endonuclease of influenza virus polymerase resides in the PA subunit. Nature 2009,458(7240),914-918","journal-title":"Nature"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"4544","DOI":"10.1016\/j.bmc.2018.07.046","volume":"26","author":"Ferro S.","year":"2018","unstructured":"Ferro S.; Gitto R.; Buemi M.R.; Karamanou S.; Stevaert A.; Naesens L.; De Luca L.; Identification of influenza PA-Nter endonuclease inhibitors using pharmacophore- and docking-based virtual screening. Bioorg Med Chem 2018,26(15),4544-4550","journal-title":"Bioorg Med Chem"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"RRN1052","DOI":"10.1371\/currents.RRN1052","volume":"1","author":"Kuzuhara T.","year":"2009","unstructured":"Kuzuhara T.; Iwai Y.; Takahashi H.; Hatakeyama D.; Echigo N.; Green tea catechins inhibit the endonuclease activity of influenza A virus RNA polymerase. PLoS Curr 2009,1,RRN1052","journal-title":"PLoS Curr"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"9024","DOI":"10.1128\/JVI.00911-09","volume":"83","author":"Zhao C.","year":"2009","unstructured":"Zhao C.; Lou Z.; Guo Y.; Ma M.; Chen Y.; Liang S.; Zhang L.; Chen S.; Li X.; Liu Y.; Bartlam M.; Rao Z.; Nucleoside monophosphate complex structures of the endonuclease domain from the influenza virus polymerase PA subunit reveal the substrate binding site inside the catalytic center. J Virol 2009,83(18),9024-9030","journal-title":"J Virol"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"e1002830","DOI":"10.1371\/journal.ppat.1002830","volume":"8","author":"DuBois R.M.","year":"2012","unstructured":"DuBois R.M.; Slavish P.J.; Baughman B.M.; Yun M-K.; Bao J.; Webby R.J.; Webb T.R.; White S.W.; Structural and biochemical basis for development of influenza virus inhibitors targeting the PA endonuclease. PLoS Pathog 2012,8(8),e1002830","journal-title":"PLoS Pathog"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1021\/cb400400j","volume":"8","author":"Bauman J.D.","year":"2013","unstructured":"Bauman J.D.; Patel D.; Baker S.F.; Vijayan R.S.K.; Xiang A.; Parhi A.K.; Mart\u00ednez-Sobrido L.; LaVoie E.J.; Das K.; Arnold E.; Crystallographic fragment screening and structure-based optimization yields a new class of influenza endonuclease inhibitors. ACS Chem Biol 2013,8(11),2501-2508","journal-title":"ACS Chem Biol"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"e1002831","DOI":"10.1371\/journal.ppat.1002831","volume":"8","author":"Kowalinski E.","year":"2012","unstructured":"Kowalinski E.; Zubieta C.; Wolkerstorfer A.; Szolar O.H.J.; Ruigrok R.W.H.; Cusack S.; Structural analysis of specific metal chelating inhibitor binding to the endonuclease domain of influenza pH1N1 (2009) polymerase. PLoS Pathog 2012,8(8),e1002831","journal-title":"PLoS Pathog"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1002\/med.21401","volume":"36","author":"Stevaert A.","year":"2016","unstructured":"Stevaert A.; Naesens L.; The influenza virus polymerase complex: An update on its structure, functions, and significance for antiviral drug design. Med Res Rev 2016,36(6),1127-1173","journal-title":"Med Res Rev"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"3533","DOI":"10.1021\/acs.jmedchem.6b01227","volume":"60","author":"Ju H.","year":"2017","unstructured":"Ju H.; Zhang J.; Huang B.; Kang D.; Huang B.; Liu X.; Zhan P.; Inhibitors of influenza virus Polymerase Acidic (PA) Endonuclease: Contemporary developments and perspectives. J Med Chem 2017,60(9),3533-3551","journal-title":"J Med Chem"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/0042-6822(74)90276-1","volume":"61","author":"Palese P.","year":"1974","unstructured":"Palese P.; Tobita K.; Ueda M.; Compans R.W.; Characterization of temperature sensitive influenza virus mutants defective in neuraminidase. Virology 1974,61(2),397-410","journal-title":"Virology"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/9780470179727.ch3","author":"Ezelle H.J.","year":"2007","unstructured":"Ezelle H.J.; Hassel B.A.; Mechanisms of IFN Resistance by Influenza Virus. Combating the Threat of Pandemic Influenza 2007,73-97","journal-title":"Combating the Threat of Pandemic Influenza"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/j.1472-765X.1990.tb00131.x","volume":"11","author":"Nakayama M.","year":"1990","unstructured":"Nakayama M.; Toda M.; Okubo S.; Shimamura T.; Inhibition of influenza virus infection by tea. Lett Appl Microbiol 1990,11(1),38-40","journal-title":"Lett Appl Microbiol"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/0166-3542(93)90008-7","volume":"21","author":"Nakayama M.","year":"1993","unstructured":"Nakayama M.; Suzuki K.; Toda M.; Okubo S.; Hara Y.; Shimamura T.; Inhibition of the infectivity of influenza virus by tea polyphenols. Antiviral Res 1993,21(4),289-299","journal-title":"Antiviral Res"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.antiviral.2012.04.001","volume":"94","author":"Zu M.","year":"2012","unstructured":"Zu M.; Yang F.; Zhou W.; Liu A.; Du G.; Zheng L.; In vitro anti-influenza virus and anti-inflammatory activities of theaflavin derivatives. Antiviral Res 2012,94(3),217-224","journal-title":"Antiviral Res"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.antiviral.2005.06.010","volume":"68","author":"Song J-M.","year":"2005","unstructured":"Song J-M.; Lee K-H.; Seong B-L.; Antiviral effect of catechins in green tea on influenza virus. Antiviral Res 2005,68(2),66-74","journal-title":"Antiviral Res"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.antiviral.2010.08.016","volume":"88","author":"Kim Y.","year":"2010","unstructured":"Kim Y.; Narayanan S.; Chang K-O.; Inhibition of influenza virus replication by plant-derived isoquercetin. Antiviral Res 2010,88(2),227-235","journal-title":"Antiviral Res"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.phymed.2010.03.016","volume":"17","author":"Gangehei L.","year":"2010","unstructured":"Gangehei L.; Ali M.; Zhang W.; Chen Z.; Wakame K.; Haidari M.; Oligonol a low molecular weight polyphenol of lychee fruit extract inhibits proliferation of influenza virus by blocking reactive oxygen species-dependent ERK phosphorylation. Phytomedicine 2010,17(13),1047-1056","journal-title":"Phytomedicine"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.antiviral.2012.03.006","volume":"94","author":"Theisen L.L.","year":"2012","unstructured":"Theisen L.L.; Muller C.P.; EPs\u00ae 7630 (Umckaloabo\u00ae), an extract from Pelargonium sidoides roots, exerts anti-influenza virus activity in vitro and in vivo. Antiviral Res 2012,94(2),147-156","journal-title":"Antiviral Res"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.jep.2008.07.037","volume":"119","author":"Brendler T.","year":"2008","unstructured":"Brendler T.; van Wyk B-E.A.; A historical, scientific and commercial perspective on the medicinal use of Pelargonium sidoides (Geraniaceae). J Ethnopharmacol 2008,119(3),420-433","journal-title":"J Ethnopharmacol"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s10354-007-0434-6","volume":"157","author":"Conrad A.","year":"2007","unstructured":"Conrad A.; Kolodziej H.; Schulz V.; Pelargonium sidoides-extract (EPs 7630): Registration confirms efficacy and safety. Wien Med Wochenschr 2007,157(13-14),331-336","journal-title":"Wien Med Wochenschr"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1055\/s-2008-1074515","volume":"74","author":"Schoetz K.","year":"2008","unstructured":"Schoetz K.; Erdelmeier C.; Germer S.; Hauer H.; A detailed view on the constituents of EPs 7630. Planta Med 2008,74(6),667-674","journal-title":"Planta Med"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1099\/vir.0.2008\/004606-0","volume":"89","author":"Hale B.G.","year":"2008","unstructured":"Hale B.G.; Randall R.E.; Ort\u00edn J.; Jackson D.; The multifunctional NS1 protein of influenza A viruses. J Gen Virol 2008,89(Pt 10),2359-2376","journal-title":"J Gen Virol"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.antiviral.2013.06.005","volume":"99","author":"Engel D.A.","year":"2013","unstructured":"Engel D.A.; The influenza virus NS1 protein as a therapeutic target. Antiviral Res 2013,99(3),409-416","journal-title":"Antiviral Res"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1177\/1087057108318754","volume":"13","author":"Maroto M.","year":"2008","unstructured":"Maroto M.; Fernandez Y.; Ortin J.; Pelaez F.; Cabello M.A.; Development of an HTS assay for the search of anti-influenza agents targeting the interaction of viral RNA with the NS1 protein. J Biomol Screen 2008,13(7),581-590","journal-title":"J Biomol Screen"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1128\/JVI.01805-08","volume":"83","author":"Basu D.","year":"2009","unstructured":"Basu D.; Walkiewicz M.P.; Frieman M.; Baric R.S.; Auble D.T.; Engel D.A.; Novel influenza virus NS1 antagonists block replication and restore innate immune function. J Virol 2009,83(4),1881-1891","journal-title":"J Virol"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1099\/vir.0.025015-0","volume":"92","author":"Walkiewicz M.P.","year":"2011","unstructured":"Walkiewicz M.P.; Basu D.; Jablonski J.J.; Geysen H.M.; Engel D.A.; Novel inhibitor of influenza non-structural protein 1 blocks multi-cycle replication in an RNase L-dependent manner. J Gen Virol 2011,92(Pt 1),60-70","journal-title":"J Gen Virol"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1093\/nar\/gkm087","volume":"35","author":"Gog J.R.","year":"2007","unstructured":"Gog J.R.; Afonso E.S.; Dalton R.M.; Leclercq I.; Tiley L.; Elton D.; von Kirchbach J.C.; Naffakh N.; Escriou N.; Digard P.; Codon conservation in the influenza A virus genome defines RNA packaging signals. Nucleic Acids Res 2007,35(6),1897-1907","journal-title":"Nucleic Acids Res"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1177\/1087057111431488","volume":"17","author":"Cho E.J.","year":"2012","unstructured":"Cho E.J.; Xia S.; Ma L-C.; Robertus J.; Krug R.M.; Anslyn E.V.; Montelione G.T.; Ellington A.D.; Identification of influenza virus inhibitors targeting NS1A utilizing fluorescence polarization-based high-throughput assay. J Biomol Screen 2012,17(4),448-459","journal-title":"J Biomol Screen"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"9096","DOI":"10.1128\/JVI.00995-10","volume":"84","author":"Cr\u00e9pin T.","year":"2010","unstructured":"Cr\u00e9pin T.; Dias A.; Palencia A.; Swale C.; Cusack S.; Ruigrok R.W.H.; Mutational and metal binding analysis of the endonuclease domain of the influenza virus polymerase PA subunit. J Virol 2010,84(18),9096-9104","journal-title":"J Virol"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.antiviral.2013.08.002","volume":"100","author":"Kim M.","year":"2013","unstructured":"Kim M.; Kim S-Y.; Lee H.W.; Shin J.S.; Kim P.; Jung Y-S.; Jeong H-S.; Hyun J-K.; Lee C-K.; Inhibition of influenza virus internalization by (-)-epigallocatechin-3-gallate. Antiviral Res 2013,100(2),460-472","journal-title":"Antiviral Res"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"103894","DOI":"10.1016\/j.jff.2020.103894","volume":"68","author":"Onishi S.","year":"2020","unstructured":"Onishi S.; Mori T.; Kanbara H.; Habe T.; Ota N.; Kurebayashi Y.; Suzuki T.; Green tea catechins adsorbed on the murine pharyngeal mucosa reduce influenza A virus infection. J Funct Foods 2020,68,103894","journal-title":"J Funct Foods"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.fitote.2013.12.011","volume":"93","author":"Yang Z.F.","year":"2014","unstructured":"Yang Z.F.; Bai L.P.; Huang W.B.; Li X.Z.; Zhao S.S.; Zhong N.S.; Jiang Z.H.; Comparison of in vitro antiviral activity of tea polyphenols against influenza A and B viruses and structure-activity relationship analysis. Fitoterapia 2014,93,47-53","journal-title":"Fitoterapia"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1016\/j.bmcl.2007.03.041","volume":"17","author":"Furuta T.","year":"2007","unstructured":"Furuta T.; Hirooka Y.; Abe A.; Sugata Y.; Ueda M.; Murakami K.; Suzuki T.; Tanaka K.; Kan T.; Concise synthesis of dideoxy-epigallocatechin gallate (DO-EGCG) and evaluation of its anti-influenza virus activity. Bioorg Med Chem Lett 2007,17(11),3095-3098","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.antiviral.2007.07.001","volume":"76","author":"Song J.M.","year":"2007","unstructured":"Song J.M.; Park K.D.; Lee K.H.; Byun Y.H.; Park J.H.; Kim S.H.; Kim J.H.; Seong B.L.; Biological evaluation of anti-influenza viral activity of semi-synthetic catechin derivatives. Antiviral Res 2007,76(2),178-185","journal-title":"Antiviral Res"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/j.1348-0421.2002.tb02724.x","volume":"46","author":"Imanishi N.","year":"2002","unstructured":"Imanishi N.; Tuji Y.; Katada Y.; Maruhashi M.; Konosu S.; Mantani N.; Terasawa K.; Ochiai H.; Additional inhibitory effect of tea extract on the growth of influenza A and B viruses in MDCK cells. Microbiol Immunol 2002,46(7),491-494","journal-title":"Microbiol Immunol"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/molecules26134014","volume":"26","author":"Rawangkan A.","year":"2021","unstructured":"Rawangkan A.; Kengkla K.; Kanchanasurakit S.; Duangjai A.; Saokaew S.; Anti-influenza with green tea catechins: A systematic review and meta-analysis. Molecules 2021,26(13),1-16","journal-title":"Molecules"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"A41","DOI":"10.1016\/j.antiviral.2008.01.079","volume":"78","author":"Kaihatsu K.","year":"2008","unstructured":"Kaihatsu K.; Mori S.; Kato N.; Anti-Influenza A.; Virus inhibitory effect of (\u2212)-epigallocatechin-3-o-gallate fatty acid monoester derivatives. Antiviral Res 2008,78(2),A41","journal-title":"Antiviral Res"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"4249","DOI":"10.1016\/j.bmcl.2008.02.020","volume":"18","author":"Mori S.","year":"2008","unstructured":"Mori S.; Miyake S.; Kobe T.; Nakaya T.; Fuller S.D.; Kato N.; Kaihatsu K.; Enhanced anti-influenza A virus activity of (-)-epigallocatechin-3-O-gallate fatty acid monoester derivatives: Effect of alkyl chain length. Bioorg Med Chem Lett 2008,18(14),4249-4252","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"28","DOI":"10.34297\/AJBSR.2019.02.000566","volume":"2","author":"Ishida T.","year":"2019","unstructured":"Ishida T.; Review on the role of Zn ions in viral pathogenesis and the effect of Zn ions for host cell-virus growth inhibition. Am J Biomed Sci Res 2019,2(1),28-37","journal-title":"Am J Biomed Sci Res"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jviromet.2011.09.003","volume":"178","author":"Xiang D.X.","year":"2011","unstructured":"Xiang D.X.; Chen Q.; Pang L.; Zheng C.L.; Inhibitory effects of silver nanoparticles on H1N1 influenza A virus in vitro. J Virol Methods 2011,178(1-2),137-142","journal-title":"J Virol Methods"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"105071","DOI":"10.1016\/j.micpath.2021.105071","volume":"158","author":"Saadh M.J.","year":"2021","unstructured":"Saadh M.J.; Aggag M.M.; Alboghdadly A.; Kharshid A.M.; Aldalaen S.M.; Abdelrazek M.A.; Silver nanoparticles with epigallocatechingallate and zinc sulphate significantly inhibits avian influenza A virus H9N2. Microb Pathog 2021,158,105071","journal-title":"Microb Pathog"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1472-6882-11-15","volume":"11","author":"Matsumoto K.","year":"2011","unstructured":"Matsumoto K.; Yamada H.; Takuma N.; Niino H.; Sagesaka Y.M.; Effects of green tea catechins and theanine on preventing influenza infection among healthcare workers: A randomized controlled trial. BMC Complement Altern Med 2011,11(1),15","journal-title":"BMC Complement Altern Med"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"e96373","DOI":"10.1371\/journal.pone.0096373","volume":"9","author":"Ide K.","year":"2014","unstructured":"Ide K.; Yamada H.; Matsushita K.; Ito M.; Nojiri K.; Toyoizumi K.; Matsumoto K.; Sameshima Y.; Effects of green tea gargling on the prevention of influenza infection in high school students: A randomized controlled study. PLoS One 2014,9(5),e96373","journal-title":"PLoS One"}],"container-title":["Current Topics in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1568026622666220127112056","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/200579\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1568026622666220127112056","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T14:50:40Z","timestamp":1691851840000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/200579\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":124,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1568026622666220127112056","relation":{},"ISSN":["1568-0266"],"issn-type":[{"value":"1568-0266","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-10-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-13","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}